Tag Archives: Julian Ginos

New Directions on U.S. Sanctions

by Rachel K. AlpertJulian J. Ginos, and Rebecca Fate

Last month’s confirmation hearings for Treasury Secretary Janet Yellen and Secretary of State Antony Blinken have shed more light on the Biden administration’s approach to key sanctions programs. At a high level, human rights considerations are expected to loom larger in sanctions strategy going forward. Other systemic changes may be afoot as well; Yellen plans to direct Adewale Adeyemo, the nominee for Deputy Treasury Secretary, to conduct an overall review of U.S. sanctions policy, and the Biden administration has also ordered a review of sanctions as possible hindrances to COVID-19 response efforts. Below are seven areas of interest along with key takeaways thus far.

Continue reading

How Much Does The First Amendment Protect Medical Marketing?

by Julian Ginos

Often thought of as a bastion of countercultural resistance—think the Pentagon Papers, flag burning, the Nazi march in Skokie, IL—the First Amendment is enjoying a renaissance as a powerful antiregulatory tool for business interests. Citizens United, Hobby Lobby, and Zubik are some of the better-known examples of this phenomenon, but drug and device manufacturers have also made strides challenging the regulations governing them on First Amendment grounds. Continue reading